Meritor Pharmaceuticals

Meritor Pharmaceuticals was a private specialty pharmaceutical company based in New Jersey that focused on the development of novel pain management therapies. The company's lead product candidate was M-101, a proprietary topical formulation of ketamine intended for the treatment of neuropathic pain, including post-herpetic neuralgia. Meritor's approach leveraged specialized drug delivery technology to provide localized pain relief while minimizing systemic side effects. In May 2013, the company was acquired by Relmada Therapeutics as part of a strategic move to expand Relmada's portfolio of pain-focused assets. Following the acquisition, Meritor's programs were integrated into Relmada's clinical development pipeline.